CDC’s GAP Implementation Portfolio

7th Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers

March 2014
Dubai, UAE

Joseph Bresee
Epidemiology and Prevention Branch
Influenza Division
National Center for Immunization and Respiratory Diseases
CDC
Overarching Goal: to reduce global morbidity and mortality caused by influenza

Goal 1: Create the global capacity for effective monitoring and the evidence base for influenza control and prevention

Goal 2: Decrease the global impact of seasonal, novel and pandemic influenza viruses

Goal 1 focuses on surveillance, global capacity building, and communications

Goal 2 focuses on use of the capacity and data created by goal 1 towards influenza control and prevention
CDC International Strategic Plan
2011-15

Overarching Goal: to reduce global morbidity and mortality caused by influenza

Goal 1
Create the global capacity for effective monitoring and the evidence base for influenza control and prevention

Goal 2
Decrease the global impact of seasonal, novel and pandemic influenza viruses

Build capacity
Generate data
Communicate data
Make decisions / policy
### Linking of CDC and GAP II Objectives

<table>
<thead>
<tr>
<th>OBJECTIVE 1</th>
<th>OBJECTIVE 2</th>
<th>OBJECTIVE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase in seasonal vaccine use</td>
<td>Increase vaccine production capacity</td>
<td>R &amp; D</td>
</tr>
<tr>
<td>Global vaccination recommendations and facilitation of country policy development</td>
<td>Road-mapping for vaccine technology transfer</td>
<td>Landscaping on vaccine research and development</td>
</tr>
<tr>
<td>Capacity building and support for influenza surveillance systems in developing countries</td>
<td>Strategies on new approaches for technology transfer and sustainability</td>
<td>Research Agenda development</td>
</tr>
<tr>
<td>Collecting information to measure the impact of vaccination at country and regional level</td>
<td>Regulatory issues</td>
<td>Vaccine implementation research</td>
</tr>
<tr>
<td>Developing case for increased vaccine use (economic, disease reduction)</td>
<td></td>
<td>Vaccine regulatory research</td>
</tr>
</tbody>
</table>

**Build capacity** - Generate data - Communicate data - Make decisions/policy
OBJECTIVE 1
Increase in seasonal vaccine use

Global vaccination recommendations and facilitation of country policy development

Capacity building and support for influenza surveillance systems in developing countries

Collecting information to measure the impact of vaccination at country and regional level

Developing case for increased vaccine use (economic, disease reduction)

- Bilateral grants to > 40 countries’ Mini. Of Health
- Cooperative agreements with WHO/HQ and each WHO ROs
- Placement of ~20 overseas staff

International Influenza Activities: 2013 Cooperative Agreements
OBJECTIVE 1
Increase in seasonal vaccine use

Global vaccination recommendations and facilitation of country policy development

Capacity building and support for influenza surveillance systems in developing countries

Collecting information to measure the impact of vaccination at country and regional level

Developing case for increased vaccine use (economic, disease reduction)

- Address data gaps that affect policy or actions
  - Disease burden estimation
  - Risk factors, transmission, incidence data, seasonality in various settings
  - Vaccine effectiveness / efficacy
  - Vaccine program optimization
  - Antiviral effectiveness
  - Non-pharmaceutical interventions
  - Economic burden / CE of vaccination
Cooperative Agreements to support vaccine policy development and program implementation

**OBJECTIVE 1**
Increase in seasonal vaccine use

- Global vaccination recommendations and facilitation of country policy development
- Capacity building and support for influenza surveillance systems in developing countries
- Collecting information to measure the impact of vaccination at country and regional level
- Developing case for increased vaccine use (economic, disease reduction)

**Objectives:**
- Support policy decisions related to the introduction or expansion of seasonal influenza vaccine
- Support the implementation of national influenza vaccination programs

**Participating countries:**
- China, Kenya, Morocco, Uganda and Vietnam

**Timeline:**
- 3-years of activities

**Types of activities supported**
- Identify target groups
- Modeling vaccination strategies
- Training of NRAs
- Training of NITAGs
- Estimation and communication of DB
- Cost and cost-effectiveness studies
- Communications / advocacy
- Vaccine programmatic support (AE monitoring, vaccine coverage surveys)
Development and supply of LAIV candidate viruses for WHO

Goals:
- Establish a backup facility to IEM for the development and production of candidate live attenuated influenza virus (LAIV) vaccines.
- Incorporate optimization and quality control of LAIV candidates prepared by classical reassortment.
- Provide LAIV candidates to the WHO for distribution to facilities participating in the WHO vaccine production technology transfer program.

Products so far:
- LAIV candidates (influenza A(H3N2) and influenza B) for seasons 2011-2012 and 2012-2013 were generated at CDC and were sent to WHO for subsequent distribution to international partners.
- LAIV candidate for the newly emerged H7N9 virus was generated and is now under safety investigation.

Source: Dr. Julie Villanueva, Influenza Division, CDC
Comprehensive approach to enhance Influenza knowledge: Indian example

Capacity Building within Country:
- Training of clinical, epidemiologist, laboratory scientist

Surveillance:
- Early detection of viruses with pandemic potential
- Expansion of routine disease and viral surveillance
- Define seasonality by region

Disease Burden:
- Quantifying the burden of influenza in population-based settings

Vaccine Efficacy:
- IIV VE among children
- Indirect protection conferred by IIV
- LAIV VE among children
THANK YOU

PUBLISHED OCTOBER 2012
(2013 VERSION AVAILABLE SOON!)

HTTP://WWW.CDC.GOV/FLU/INTERNATIONAL/PROGRAM/INDEX.HTM